Finasteride - CAS 98319-26-7

Quick Inquiry

* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Product Name
Catalog Number
CAS Number
Molecular Weight
Molecular Formula
CAS 98319-26-7 Finasteride
White or off-white crystalline powder
Reference Reading
1. Resonance-assisted amide protonation in dutasteride hydrochloride salt
Jagadeesh Babu Nanubolu, Balasubramanian Sridhar and Krishnan Ravikumar*. CrystEngChem., 2012, 14, 2571–2578
Dutasteride (5,17-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide) is a pharmaceutically active compound, used for the treatment of benign prostatic hyper-plasia, a condition found primarily in men over the age of 50. The only other approved in this class is finasteride which predominantly inhibits type II 5-alpha reductase. Compared to finasteride, dutasteride is more potent and causes greater reduction in dihydrotestosterone concentration at equipotent doses. Dutasteride is reported to exist in three polymorph modifications as noted in 2004 and 2009 patents, and these forms are confirmed by powder X-ray diffraction. Attempts to grow single crystals of polymorphs have yielded a novel form of dutasteride from ethanol. The simulated pattern of this form has many similarities to the pattern reported in 2009 patent.
2. Antrodan, A β-glucan obtained from Antrodia cinnamomea mycelia, is beneficial to benign prostate hyperplasia
Chiung-Chi Peng, Yi-Ting Lin, Kuan-Chou Chen,* Charng-Cherng Chyau* and Robert Y. Peng. Food Funct.,2015, 6,635–645
Benign prostatic hyperplasia (BPH) is one of the most common diseases and usually occurs in men in their 50s. 80% of men in their 70s suffer from BPH-related lower urinary tract symptoms (LUTS), which has now become an atypical direct cause of mortality. Biochemically, BPH is considered to be an imbalance between androgen–estrogen, overexpression of stromal and epithelial growth factors, cytokines, and steroid hormones. Pathologically, BPH is characterized by hyperplasic epithelium and stromal growth that emerges into numerous microscopic and macroscopic nodules in the prostate gland. The clinical care for BPH usually involves α-blockers, 5α-reductase inhibitors (e.g., finasteride), and surgery therapy, or the combined treatment. Instead of therapeutic agents that can cause severe side effects, plant extracts are frequently used to treat BPH. Currently, phytotherapeutic agents are emerging and are frequently used as a complementary alternative treatment of BPH. Other nonmedication agents include zinc, soy/tofu, selenium, vitamin E, and amino acids.
3. Potential of grape seed-derived polyphenols extract for protection against testosterone- induced benign prostatic hyperplasia in castrated rats
Yongfang Lei, Dong Liu, Xiuhua Rena and Jinglou Chen*. RSC Adv.,2014, 4, 62996–63004
Surgery and drug therapies are themost common treatments for BPH. Obviously, drug therapies have much more advantages. Unfortunately, there are usually several adverse effects during the long term medication period. Finasteride tablet, a 5-a-reductase (5AR) inhibitor and set as the positive control in this study, is one of the most commonly used clinical agents for the treatment of BPH. However, good therapeutic effect seems to only emerge many years later from the beginning of the treatment.
4. Spectrofluorimetric study of finasteride and bovine serum albumin interaction and its application for quantitative determination of finasteride in tablet dosage form
Ali Saber Abdelhameed,* Amer M. Alanazi and Adnan A. Kadi. Anal. Methods,2015, 7,5096–5102
Finasteride (FIN; N-(1,1-dimethylethyl)-3-oxo-(5a,17b)-4-azaandrost-1-ene-17-carboxamide; Fig. 1), is a type II 5-alpha-reductase inhibitor. 5-Alpha-reductase is an intracellular enzyme that converts the androgen testosterone into 5a-dihydrotestosterone. FIN was developed by Merck & Co., Inc. (New Jersey, USA), and is marketed under the names Proscar (FIN 5mg) and Propecia (FIN 1 mg) tablets. Proscar was approved by the FDA in 1992 to treat symptoms of benign prostatic hyperplasia (BPH) in men and to reduce the risk of urinary retention or the need for surgery related to BPH. Propecia was also approved by the FDA in 1997 for use in males only for the treatment of male pattern hair loss (androgenetic alopecia). Serum albumins are multi-functional storage proteins and transport carriers for many ligands, and they are the main circulatory proteins in various organisms. Their interaction with drugs can affect the distribution volume and elimination rate of drugs. Therefore, investigating drug–albumin binding helps clarify drug metabolism and transport pathways. Bovine serum albumin (BSA) is an important albumin that is involved in binding, transport, and delivery of several molecules.
2005 - BOC Sciences | All rights reserved